Last updated: February 18, 2025
Sponsor: Nobelpharma
Overall Status: Completed
Phase
3
Condition
Menstrual Disorders
Severe Premenstrual Symptom
Female Hormonal Deficiencies/abnormalities
Treatment
NPC-01
Placebo
IKH-01
Clinical Study ID
NCT01129102
NPC-01-2
Ages > 16 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- dysmenorrhea
Exclusion
Exclusion Criteria:
severe hepatopathy
pregnant woman
Study Design
Total Participants: 215
Treatment Group(s): 3
Primary Treatment: NPC-01
Phase: 3
Study Start date:
May 01, 2010
Estimated Completion Date:
April 30, 2011